BVXV - BiondVax stock +6% on license agreement to develop antibodies

2023-06-05 13:14:14 ET

• U.S.-listed shares of BiondVax Pharmaceuticals ( NASDAQ: BVXV ) jumped as much as 32% on Monday on a license agreement to develop antibodies.
• BVXV stock was last up 6.3% to $1.82 in afternoon trade.
• The micro-cap biotech signed an exclusive worldwide license agreement with the Max Planck Society and the University Medical Center Gottingen (UMG) to develop and commercialize antibodies as treatments for all potential indications, starting with psoriasis and psoriatic arthritis.
• The agreement is part of BVXV's ongoing broad-based collaboration with the Max Planck Society and UMG.

For further details see: